TTrialPathMatch Me to Trials
← Back to trials
RecruitingHepatitis BCirrhosis, LiverChronic Liver Disease

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

Sponsor: Mercy Medical Center

You may qualify if…

  • \- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer \< 10 mIU/ml) will be recruited.

You may not qualify if…

  • Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.
  • Those who had previous exposure to hepatitis B.
  • Post liver transplant patients.
  • Less than 18 years old.

Where it's recruiting

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT04588077 · last updated 2024-11-19